Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 Next >
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Host First Quarter 2022 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Pricing of $100.0 Million Public Offering
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Proposed Public Offering
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Present at Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports 2021 Third Quarter Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
From Zymeworks Inc.
Via Business Wire
Tickers ALXO ZYME
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS